As of 2025-01-14, the Relative Valuation of BioMark Diagnostics Inc (BUX.CN) is (0.02) CAD. This relative valuation is based on P/E multiples. With the latest stock price at 0.20 CAD, the upside of BioMark Diagnostics Inc based on Relative Valuation is -109.7%.
The range of the Relative Valuation is (0.02) - (0.14) CAD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 0.7x - 6.9x | 0.9x |
| Forward P/E multiples | -1.1x - 6.5x | 0.9x |
| Fair Price | (0.02) - (0.14) | (0.02) |
| Upside | -107.8% - -170.2% | -109.7% |
| Date | P/E |
| 2024-12-24 | -9.23 |
| 2024-12-23 | -8.77 |
| 2024-12-17 | -9.23 |
| 2024-12-16 | -9.00 |
| 2024-12-13 | -9.00 |
| 2024-12-09 | -10.39 |
| 2024-12-02 | -10.16 |
| 2024-11-29 | -10.39 |
| 2024-11-28 | -10.39 |
| 2024-11-27 | -9.93 |
| 2024-11-25 | -9.70 |
| 2024-11-22 | -9.46 |
| 2024-11-21 | -8.31 |
| 2024-11-18 | -10.16 |
| 2024-11-15 | -10.62 |
| 2024-11-11 | -11.31 |
| 2024-11-08 | -10.62 |
| 2024-11-06 | -10.62 |
| 2024-11-05 | -10.62 |
| 2024-11-04 | -10.85 |
| 2024-11-01 | -10.85 |
| 2024-10-25 | -11.08 |
| 2024-10-24 | -11.08 |
| 2024-10-22 | -11.08 |
| 2024-10-10 | -11.31 |
| 2024-10-09 | -11.08 |
| 2024-10-08 | -10.62 |
| 2024-10-03 | -11.54 |